Kernal Biologics YC Başvurusu

Summer 2020Active

Kernal Biologics, Healthcare şirketi olarak Summer 2020 grubunda Y Combinator'dan geçti. Aşağıda: şirketin ne yaptığı, kimin kurduğu ve gerçek YC formunda yeniden yapılandırılmış YC başvurusu.

YC grubu: Summer 2020
Sektör: HealthcareTherapeutics
Ekip büyüklüğü: 20
Durum: Active
Lansmanı Yapıldı: 2020

Kurucular

Yusuf ErkulFounder
Jeff OzdemirFounder
Burak YILMAZFounder

Kernal Biologics ne yapar

Kernal Bio is a biotech company pioneering mRNA 2.0 immunotherapies. We leverage selective mRNA-LNP technology to treat cancer and autoimmune diseases with precision, ensuring targeted cell delivery and minimal off-target effects. Our KR-402 program achieves over 90% delivery efficiency with T-cell-targeted LNPs, enabling direct CAR-T programming within the body and resulting in B-cell depletion within a week. Kernal Bio is led by a team with experience from MIT, Harvard, Merck, and BMS, boasting three FDA-approved therapies and over 120 patents. Based in Cambridge, MA, we are backed by Hummingbird Ventures, Amgen Ventures, HBM, and even NASA. With roots at MIT, Harvard and Biopharma, Kernal’s management team has deep expertise in mRNA therapeutics space. CEO Yusuf Erkul, M.D., M.B.A. is a successful drug hunter whose research at Merck enabled an FDA-approved drug for ovarian cancer. President Burak Yilmaz, M.S., previously founded Sentegen, a thriving synthetic biology company which commercializes synthetic DNA, RNA, and diagnostic kits for genetic and infectious diseases. Sr. VP of R&D Manfred Kraus is a leader in immuno-oncology, who was most recently Scientific Sr. Director at Bristol-Myers Squibb (BMS).

Kernal Biologics'in YC başvurusu, yeniden yapılandırılmış

Y Combinator başvurusu

Kernal Biologics, Summer 2020 dönemi. Gerçek form soruları, herkese açık verilerden yanıtlandı.

Founders2
Company7
Progress7
Idea4
Equity3
Curious2
Batch Preference1

Company

Company name

Kernal Biologics

Describe what your company does in 50 characters or less.

mRNA 2.0 therapies targeting specific cells

What is your company going to make? Please describe your product and what it does or will do.

We're building selective mRNA-LNP immunotherapies that deliver mRNA precisely to specific immune cells. Our lead program, KR-402, targets T cells to program CAR-T therapies directly in the body and can deplete B cells within a week. This lets us treat cancer and autoimmune diseases with fewer off-target effects than current mRNA approaches.

Where do you live now, and where would the company be based after YC?

We live in Cambridge, MA, and Kernal is based there. After YC, we'd remain in Cambridge because that's where our team, science, and investors are concentrated.

Explain your decision regarding location.

Cambridge is a biotech hub with access to top academic talent and proximity to investors, which is critical for developing complex mRNA therapeutics. Being near MIT and Harvard also helps us recruit and collaborate on cutting-edge science.

Tam başvuruda 21 ek cevap

Founders, Progress, Idea, Equity, Curious, Batch Preference tam sürümde. YC Insights'ta, diğer her YC grubu yanında açmak için ücretsiz bir hesap oluşturun.

Tüm başvuruyu gör

Sıkça Sorulan Sorular

Bu, Kernal Biologics şirketinin gerçek YC başvurusu mu?

Hayır. Y Combinator gönderilen başvuruları gizli tutar. Bu bir yeniden yapılandırmadır: gerçek YC form soruları, Kernal Biologics'in kamuya açık verilerinden (lansman notları, kurucu geçmişleri, ürün açıklaması) yanıtlanmıştır. Kernal Biologics gibi bir şirketin YC'ye kendisini nasıl sunacağını gösterir, gönderdikleri metni değil.